Service providers

Bridge 2 Health

Solution provided
Technological/Validation solutions
Supplier indentity
General description
B2H is the designated contact point to simplify and improve the access to a broad platform of healthcare solutions developed by medical and scientific research teams of the University Hospital of Liege and University of Liege in Belgium. B2H aims to match the know-how of researchers, clinicians and technology managers with the needs of your organization. Though our network of technological and scientific expertise, B2H can support projects at every stage from early discovery, through preclinical up to translational and personalized medicine. 
Type of supplier
Incubator Services, Lab/scientific services platform
Sector of activity:
Biobanks, Biomarkers / Biomarker Discovery, Business development, Cancer / Oncology, Cardiovascular, Dentistry, Drug Discovery / Research & Development, Gastroenterology, Gene / Cell Therapy, Genomics, Hematology, Imaging, Inflammation / Autoimmune Disorders, Metabolomics, Molecular biology, Musculoskeletal, Neurology /Central Nervous System, Nuclear medicine, Personalized Medicine, Pneumology, Proteomics, Regenerative Medicine, Respiratory / Asthma, Rheumatology, Toxicology, Transcriptomics, Translational medecine
Activity description
Services provided
- Analytical platform - Genomic & Proteomic platforms - Virus Vector platform - Protein Production & Characterization platform - Cell imaging - Preclinical imaging - Radiopharmaceutical Development & Production - Cell Therapy Manufacturing - Phase I Unit - Clinical Trial Center
Terms of availability for SMEs
Service availability depends on lab capacities and utilization rate by other healthcare companies.
Quality labels and accreditations
Depends on lab accreditation (GMP, GLP, ISO,...)
Contact information
Name
Caroline THIELEN
Function
COO
Phone number
+32 (0) 4 242 77 60
Address
Avenue de l'Hopital, 11 Quartier hopital CHU-Tour 5: GIGA +3
4000 Liege
Belgium

Upcoming events

With the IVDR coming into force, manufacturers and developers of in vitro diagnostics and biomarkers must comply with the new regulatory requirements. Many companies, especially small and medium-sized enterprises, face major hurdles in this transition.

Agenda

Mo Tu We Th Fr Sa Su
 
 
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31